Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Novacyt de volgende biotech raket!

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,630   -0,006   (-0,94%) Dagrange 0,626 - 0,645 149.116   Gem. (3M) 1,2M

Novacyt de volgende biotech raket!

Volgen
70.761 Posts
Pagina: «« 1 ... 914 915 916 917 918 ... 3539 »» | Laatste | Omlaag ↓
  9. forum rang 10 voda 14 mei 2020 08:13
    quote:

    Limt89 schreef op 14 mei 2020 08:09:

    PB

    www.voxmarkets.co.uk/rns/announcement...
    Bedankt plus dikke AB!

    2020 trading and outlook
    The Primerdesign and Lab21 businesses started the year strongly, with an order book significantly higher than the beginning of 2019 and with working capital to fully restore the Group’s supply chain through the first half of 2020.

    In early January 2020, Novacyt commenced the development of a new test in response to the emerging novel coronavirus (COVID-19) threat emerging from China. Primerdesign launched its test in late January 2020 to become one of the world’s first molecular tests for the SARS-CoV-2 virus. The test was the first to achieve CE-IVD status and was subsequently approved for emergency use by the US Food and Drug Administration, the World Health Organisation and other regulatory bodies. The Company quickly established the need to develop significant manufacturing capacity and today has eight dedicated manufacturing sites capable of producing COVID-19 tests at an output rate of more than ten million tests per month, which Novacyt expects to achieve from June 2020 onwards. Through its investment in raw materials and manufacturing, the Company is now in a position to service significant and expected growth in demand for its COVID-19 test.

    Sales, orders and commitments to purchase the test since the initial launch have significantly exceeded expectations and have been transformational for the Group; all indications are that the positive financial effects of this will continue. This is additional revenue to Novacyt’s other operations at Primerdesign and Lab21 Products. The Directors believe the significant demand for the Company’s COVID-19 test will continue through to the end of the year, and may extend well into 2021, as the global demand for COVID-19 testing continues to increase. Further revenues are also expected from the launch of the Company’s COVID-19 related products described later, which include the Exsig™ Direct extraction reagent and mobile COVID-19 testing.

    In the four months to end of April 2020, the Group achieved an EBITDA margin in excess of 50% driven by the success of the COVID-19 test. Should the current level of activity continue for the full year, it will be financially transformational for the business and orders suggest a continuing increase in the level of sales activity. Significant levels of cash are also expected to be generated from this level of profitability and as of the end of April 2020, the Group had a net cash balance of €9.2m (cash as at 31 December 2019 of €1.8m). Given the low capital intensity of Novacyt’s manufacturing process, a significant proportion of the Group’s EBITDA should be converted to cash.

    In addition, the Directors believe the successful development, launch and sale of the COVID-19 test will have a positive, long-term effect on the business. As well as reinforcing the expertise within the business, the Company now has a new and significantly increased base of global customers. The Company is already experiencing increased demand for its B2B molecular design and development capabilities and the Board believes these opportunities will extend to Novacyt’s extensive product portfolio.
  11. forum rang 10 voda 14 mei 2020 08:19
    New COVID-19 innovation
    In addition to rapidly developing a test for COVID-19, the Company is working on further innovations to support laboratories during the pandemic. These innovations include:

    Direct-to-PCR extraction reagent called Exsig™ Direct to remove the need for RNA extraction reagents containing magnetic-beads. This reagent may now launch in two formats to accommodate different laboratory work-flows. The products are undergoing final clinical validation and expected to launch during June 2020. These reagents are expected to significantly improve laboratory workflow, reduce cycle times, increase throughput and reduce costs for COVID-19 testing.
    In addition to our own Direct-to-PCR extraction reagents we also plan to launch Exsig™ Mag which is an RNA extraction reagent using magnetic beads for those laboratories that still wish to use the automated RNA extraction systems that they have invested in.
    High throughput COVID-19 tests will be available in bulk format with each kit containing 1,536 tests for use in 384 well format instead of the smaller 96 well plate format. This product will be very helpful for large high-throughput clinical laboratories and will launch in June 2020.
    Mobile COVID-19 testing is being evaluated using the Company’s q16 instrument combined with its Exsig™ Direct reagent and genesig® COVID-19 test. Trials in clinical laboratories are expected to complete in June 2020 and this mini-laboratory combination may be used in remote locations, such as care homes.
    Graham Mullis
    Chief Executive Officer
    Novacyt S.A.
  12. Nait Soesen 14 mei 2020 08:20
    www.voxmarkets.co.uk/rns/announcement...

    Financial highlights

    Adjusted EBITDA of €0.2 million in 2019 compared with €0.6 million in 2018
    Third consecutive year of positive EBITDA for the Group
    Reduction in adjusted EBITDA reflects reduced sales in 2019 due to working capital constraints during the year
    Group consolidated revenue decreased by 5% (6% at CER) to €13.1m (£11.5m) in 2019 compared with €13.7m (£12.1m) in 2018
    Excluding the Clinical Lab, which was sold in July 2019, Group revenue reduced by 2% (3% CER)
    Primerdesign grew 1% year-on-year to €6.3m in 2019 compared with €6.2m in 2018
    American sales were up 13% year-on-year driven by increased sales through Primerdesign’s key US customers
    Group gross margin continued to improve and increased to 64% in 2019 from 63% in 2018
    Continues a trend of increased gross margin every year since 2014
    Improvement due to the exit from the lower margin Clinical Lab business and Primerdesign increasing its share of Group revenue to 48% (2018: 45%)
    Primerdesign’s strong gross margin increased to 85% (2018: 84%)
    Successfully sold NOVAprep® and the Clinical Lab during 2019, each realising a total consideration of €0.4m
    Refinancing of borrowings in November 2019 through a €5m bond with Harbert European Growth Capital
    Cash at year end of €1.8m (£1.5m) compared with €1.1m (£1.0m) in 2018
  13. forum rang 10 DeZwarteRidder 14 mei 2020 08:20
    quote:

    voda schreef op 14 mei 2020 08:13:

    [...]
    Bedankt plus dikke AB!

    2020 trading and outlook
    The Primerdesign and Lab21 businesses started the year strongly, with an order book significantly higher than the beginning of 2019 and with working capital to fully restore the Group’s supply chain through the first half of 2020.

    In early January 2020, Novacyt commenced the development of a new test in response to the emerging novel coronavirus (COVID-19) threat emerging from China. Primerdesign launched its test in late January 2020 to become one of the world’s first molecular tests for the SARS-CoV-2 virus. The test was the first to achieve CE-IVD status and was subsequently approved for emergency use by the US Food and Drug Administration, the World Health Organisation and other regulatory bodies. The Company quickly established the need to develop significant manufacturing capacity and today has eight dedicated manufacturing sites capable of producing COVID-19 tests at an output rate of more than ten million tests per month, which Novacyt expects to achieve from June 2020 onwards. Through its investment in raw materials and manufacturing, the Company is now in a position to service significant and expected growth in demand for its COVID-19 test.

    Sales, orders and commitments to purchase the test since the initial launch have significantly exceeded expectations and have been transformational for the Group; all indications are that the positive financial effects of this will continue. This is additional revenue to Novacyt’s other operations at Primerdesign and Lab21 Products. The Directors believe the significant demand for the Company’s COVID-19 test will continue through to the end of the year, and may extend well into 2021, as the global demand for COVID-19 testing continues to increase. Further revenues are also expected from the launch of the Company’s COVID-19 related products described later, which include the Exsig™ Direct extraction reagent and mobile COVID-19 testing.

    In the four months to end of April 2020, the Group achieved an EBITDA margin in excess of 50% driven by the success of the COVID-19 test. Should the current level of activity continue for the full year, it will be financially transformational for the business and orders suggest a continuing increase in the level of sales activity. Significant levels of cash are also expected to be generated from this level of profitability and as of the end of April 2020, the Group had a net cash balance of €9.2m (cash as at 31 December 2019 of €1.8m). Given the low capital intensity of Novacyt’s manufacturing process, a significant proportion of the Group’s EBITDA should be converted to cash.

    In addition, the Directors believe the successful development, launch and sale of the COVID-19 test will have a positive, long-term effect on the business. As well as reinforcing the expertise within the business, the Company now has a new and significantly increased base of global customers. The Company is already experiencing increased demand for its B2B molecular design and development capabilities and the Board believes these opportunities will extend to Novacyt’s extensive product portfolio.
    Dit valt natuurlijk erg tegen gezien de absurde verwachtingen van dit forum.
    Blijkbaar hebben ze ca 7 miljoen winst gemaakt t/m eind april en de brutowinstmarge is slechts ca 50%.
    En alle winst met corona is en blijft een eenmalige zaak.
  14. TheFett 14 mei 2020 08:21


    The Company quickly established the need to develop significant manufacturing capacity and today has eight dedicated manufacturing sites capable of producing COVID-19 tests at an output rate of more than ten million tests per month, which Novacyt expects to achieve from June 2020 onwards. Through its investment in raw materials and manufacturing, the Company is now in a position to service significant and expected growth in demand for its COVID-19 test.

    Vanaf juni gaat Novacyt dus meer dan 10 miljoen tests per maand produceren!
  16. [verwijderd] 14 mei 2020 08:26
    quote:

    voda schreef op 14 mei 2020 08:13:

    [...]

    In the four months to end of April 2020, the Group achieved an EBITDA margin in excess of 50% driven by the success of the COVID-19 test. Should the current level of activity continue for the full year, it will be financially transformational for the business and orders suggest a continuing increase in the level of sales activity. Significant levels of cash are also expected to be generated from this level of profitability and as of the end of April 2020, the Group had a net cash balance of €9.2m (cash as at 31 December 2019 of €1.8m). Given the low capital intensity of Novacyt’s manufacturing process, a significant proportion of the Group’s EBITDA should be converted to cash.
    factor 5, 1.
  18. [verwijderd] 14 mei 2020 08:31
    quote:

    Zuurtje schreef op 14 mei 2020 08:26:

    De zwarte ridder er weer? Altijd negatief..probeert nog een paar aandeeltjes voor een prikkie op te rapen..hahaha
    Eens, maar de 50% is inderdaad heel wat anders dan wat hier voorspeld, berekend en gegokt is!

    Voorals nog doet deze publicatie weinig met de Pre-open koers.

70.761 Posts
Pagina: «« 1 ... 914 915 916 917 918 ... 3539 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee